Torno Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Torno Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,500	Closed	-$107K	–	399
2023 Q4	$107K	Buy	+1,500	New	+$86.3K	0.02%	181

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Torno Capital's ITCI Position: Q1 2024 in Review

Torno Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 1,500 shares — an estimated $107K sold.

Torno Capital first reported a position in ITCI in Q4 2023 and held it in 1 quarter. The position peaked at $107K in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

Torno Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
Torno Capital sold 1,500 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $107K.
Torno Capital first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 1 quarter.
Torno Capital's Intra-Cellular Therapies Inc. position peaked at $107K in Q4 2023.
346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Torno Capital's 13F filing for Q1 2024, filed 15 May 2024.